Claims for Patent: 10,526,581

Summary for Patent: 10,526,581

Title:	Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof
Abstract:	The present invention relates to endogenous cardiac stem-progenitor cells (eCSCs). Provided herein are c-kitpos CD166pos eCSCs that are negative for the hematopoietic marker, CD45 and the mast cell marker, Tryptase. These single cell derived eCSCs can differentiate into a variety of specific cell types corresponding to the derivatives of the three germ layers. Also provided herein is a stage-specific TGF-P-Family/Wnt-Inhibitor cocktail for modulating in vitro myogenic specification and maturation of c-kitpos eCSCs. Also provided herein are methods of modulating eCSCs clonal expansion and differentiation. Also provided herein are screening assays for small organic molecules that modulate early cardiomyogenic progenitor cells. The invention further relates to the use of these modulated cells in prophylactic and therapeutic methods, including in pharmaceutical compositions of such cells, growth factors and/or small organic compounds. Finally, the invention relates to the use of such differentiated cells in transplantation and medical treatments.
Inventor(s):	Nadal-Ginard; Bernardo (Chestnut Hill, MA)
Assignee:
Application Number:	14/762,760
Patent Claims:	1. A method for promoting autologous cardiac tissue regeneration in a subject with cardiac tissue damage comprising administering to the subject a therapeutically effective amount of allogeneic adult cardiac stem-progenitor cells that express c-Kit and CD166 and lack detectable expression of CD45, CD34, CD31, Tryptase and Wilms Tumor-1 in the absence of an immunosuppressive agent to promote subject-mediated autologous regeneration of cardiac tissue, assessing left ventricular ejection fraction in the subject after administration of the allogeneic adult cardiac stem-progenitor cells, wherein the allogeneic adult cardiac stem-progenitor cells optionally express one or more markers selected from the group consisting of CD90, PDGFr.alpha., CXCR4, Nestin, CD146, Flk-1, Klf-4, Nanog and Sox-2; wherein the allogeneic adult cardiac stem-progenitor cells lack detectable expression of Oct-4 protein; wherein the therapeutically effective amount comprises 1.times.10.sup.7 to 1.times.10.sup.8 cells; and wherein autologous cardiac tissue regeneration in the subject comprises preventing deterioration of the left ventricular ejection fraction that is observed in an untreated control subject with cardiac tissue damage. 2. The method of claim 1, wherein the subject exhibits myocardium damage and the allogeneic adult cardiac stem-progenitor cells are administered intra-coronary or directly into the cardiac tissue of the subject, wherein the allogeneic adult cardiac stem-progenitor cells spontaneously home and nest to the damaged myocardium of the subject. 3. The method of claim 1, further comprising treating a deficit of endogenous cardiac stem-progenitor cells in the subject via peripheral circulation. 4. The method of claim 1, wherein the allogeneic adult cardiac stem-progenitor cells are administered together with at least one of IGF-1, Wnt3a, FGF-2, HGF, neuroregulin, or periostin. 5. The method of claim 1, further comprising ameliorating fractional shortening in the subject. 6. The method of claim 1, further comprising forming new capillary structures in the subject. 7. The method of claim 1, further comprising improving at least one parameter of diastolic heart function in the subject. 8. The method of claim 1, wherein the subject has cardiac tissue damage caused by one or more of myocardial infarction, stroke, hypotension, cardiac arrest, ischemia, inflammation, radiation damage, or heart-lung bypass. 9. A method for promoting cardiac tissue regeneration in a subject with a defect in endogenous stem-progenitor cells comprising administering to the subject via peripheral circulation, a therapeutically effective amount of cardiac stem-progenitor cells that express c-Kit and CD166 and lack detectable expression of CD45, CD34, CD31, Tryptase and Wilms Tumor 1 in the absence of an immunosuppressive agent, thereby promoting subject-mediated regeneration of cardiac tissue, assessing left ventricular ejection fraction in the subject after administration of the cardiac stem-progenitor cells, wherein the cardiac stem-progenitor cells optionally express one or more markers selected from the group consisting of CD90, PDGFr.alpha., CXCR4, Nestin, CD146, Flk-1, Klf-4, Nanog and Sox-2; wherein the cardiac stem-progenitor cells lack detectable expression of Oct-4 protein; wherein the therapeutically effective amount comprises 1.times.10.sup.7 to 1.times.10.sup.8 cells; and wherein an increase in left ventricular ejection fraction after administration of the cardiac stem-progenitor cells compared to that observed in an untreated control subject with a defect in endogenous stem-progenitor cells corresponds to cardiac tissue regeneration in the subject. 10. The method of claim 9, wherein the cardiac stem-progenitor cells are administered together with at least one of IGF-1, Wnt3a, FGF-2, HGF, neuroregulin, or periostin. 11. The method of claim 10, wherein the cells are administered through intracoronary injection with a catheter or directly into the myocardium of the subject either trans-endocardically or trans-epicardically. 12. The method of claim 9, wherein the cardiac stem-progenitor cells are HLA matched or allogeneic. 13. The method of claim 9, wherein the defect in the endogenous stem-progenitor cells of the subject is mediated by exposure to a cardiotoxic drug, optionally wherein the cardiotoxic drug is Herceptin, Doxorubicin, a tyrosine kinase receptor inhibitor or an anthracycline. 14. The method of claim 9, wherein the defect in the endogenous stem-progenitor cells of the subject is caused by a mutation in a gene encoding a sarcomeric protein. 15. The method of claim 9, further comprising ameliorating progressive deterioration in left ventricular ejection fraction in the subject or forming new capillary structures in the subject. 16. The method of claim 9, further comprising improving at least one parameter of diastolic heart function in the subject. 17. A method for promoting autologous cardiac tissue regeneration in a subject with cardiac tissue damage comprising: administering to the subject a therapeutically effective amount of IGF-1, HGF, and allogeneic adult cardiac stem-progenitor cells that express c-Kit and CD166 and lack detectable expression of CD45, CD34, CD31, Tryptase and Wilms Tumor-1 in the absence of an immunosuppressive agent to promote subject-mediated autologous regeneration of cardiac tissue, assessing left ventricular ejection fraction in the subject after administration of the allogeneic adult cardiac stem-progenitor cells, wherein the allogeneic adult cardiac stem-progenitor cells optionally express one or more markers selected from the group consisting of CD90, PDGFr.alpha., CXCR4, Nestin, CD146, Flk-1, Klf-4, Nanog and Sox-2, wherein the allogeneic adult cardiac stem-progenitor cells lack detectable expression of Oct-4 protein; wherein the therapeutically effective amount comprises 1.times.10.sup.7 to 1.times.10.sup.8 cells; and wherein an increase in left ventricular ejection fraction after administration of the allogeneic adult cardiac stem-progenitor cells compared to that observed in an untreated control subject with cardiac tissue damage corresponds to autologous cardiac tissue regeneration in the subject.

Details for Patent 10,526,581

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2033-01-24
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2033-01-24